Assignee
ABBVIE BIOTHERAPEUTICS INC
US·31 granted patents·35 pending applications·160 citations·filing 2012–2024
Top patents by PatentIndex Score
66 records- 0196US9914783B1Anti-PD-1 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Mar 13, 2018·61 cites·17 claims
- 0292US10233258B2Bispecific binding proteins that bind CD40 and mesothelinABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Mar 19, 2019·16 cites·10 claims
- 0389US9260528B2DAC HYP compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Feb 16, 2016·7 cites·8 claims
- 0488US10875921B2Anti-4-1BB antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Dec 29, 2020·4 cites·18 claims
- 0588US10053720B2Vectors and host cells comprising a modified SV40 promoter for protein expressionABBVIE BIOTHERAPEUTICS INC·Filed 2016·Granted Aug 21, 2018·5 cites·19 claims
- 0688US10040864B2Anti-OX40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Aug 7, 2018·4 cites·18 claims
- 0788US10023645B1Anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Jul 17, 2018·5 cites·11 claims
- 0888US9676860B2DAC HYP compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Jun 13, 2017·7 cites·8 claims
- 0988US9587007B2CTLA4 proteins and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2014·Granted Mar 7, 2017·8 cites·19 claims
- 1087US10011657B2Anti-CS1 antibodies and antibody drug conjugatesABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Jul 3, 2018·4 cites·16 claims
- 1187US9815903B2DAC HYP compositionsABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Nov 14, 2017·5 cites·12 claims
- 1287US9340619B2DAC HYP compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted May 17, 2016·6 cites·4 claims
- 1387US9315573B2Anti-TNF-alpha antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2014·Granted Apr 19, 2016·9 cites·36 claims
- 1486US8883971B2CTLA4 proteins and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Granted Nov 11, 2014·7 cites·19 claims
- 1584US9815893B2Anti-VEGF antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Granted Nov 14, 2017·6 cites·13 claims
- 1681US2023321271A1ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USEABBVIE BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1780US2022112304A1Anti-ox40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 1879US9175081B2Therapeutic use of anti-CS1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Granted Nov 3, 2015·2 cites·36 claims
- 1979US2022119542A1Anti-cd40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2078US10400041B2Nucleic acid molecules encoding anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Granted Sep 3, 2019·1 cites·20 claims
- 2177US10519243B2Anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Dec 31, 2019·1 cites·9 claims
- 2277US2021277137A1Anti-cd40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2376US12478689B2Anti-CD19 antibody drug conjugatesABBVIE BIOTHERAPEUTICS INC·Filed 2024·Granted Nov 25, 2025·0 cites·13 claims
- 2476US12121589B2Anti-CD19 antibody drug conjugatesABBVIE BIOTHERAPEUTICS INC·Filed 2023·Granted Oct 22, 2024·0 cites·3 claims
- 2576US10604584B2Anti-OX40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Granted Mar 31, 2020·0 cites·2 claims
- 2675US2021017289A1Anti-ox40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2774US2021024642A1Anti-cd40 antibody and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2873US10844131B2Anti-CD40 antibodyABBVIE BIOTHERAPEUTICS INC·Filed 2019·Granted Nov 24, 2020·0 cites·9 claims
- 2973US2020181282A1Anti-ox40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3072US10597460B2Anti-CD40 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Granted Mar 24, 2020·0 cites·2 claims
- 3171US10730953B2Anti-PD-1 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Granted Aug 4, 2020·0 cites·2 claims
- 3270US10556962B2Anti-OX40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Feb 11, 2020·0 cites·15 claims
- 3370US9072725B2Method for treating psoriasisABBVIE BIOTHERAPEUTICS INC·Filed 2014·Granted Jul 7, 2015·1 cites·3 claims
- 3469US2020157230A1Dac hyp compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3569US2020031929A1Therapeutic use of anti-cs1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3667US2020317808A1Anti-pd-1 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3767US2018346593A1Anti-ox40 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3866US9279016B2Methods for identifying antibodies with reduced immunogenicityABBVIE BIOTHERAPEUTICS INC·Filed 2013·Granted Mar 8, 2016·1 cites·12 claims
- 3963US2022211846A1Abt-165 in combination with folinic acid, 5-fluorouracil, and irinotecan for the treatment of cancersABBVIE BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4063US2020308290A1Anti-cd25 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4162US10308713B2Anti-CS1 antibodies and antibody drug conjugatesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Granted Jun 4, 2019·0 cites·20 claims
- 4262US2018127506A1Dac hyp compositions and methodsABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4361US10442859B2Therapeutic use of anti-CS1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2015·Granted Oct 15, 2019·0 cites·12 claims
- 4460US2019062797A1Vectors and host cells comprising a modified SV40 promoter for protein expressionABBVIE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4559US10150814B2Fc variants with improved complement activationABBVIE BIOTHERAPEUTICS INC·Filed 2014·Granted Dec 11, 2018·0 cites·14 claims
- 4659US2017342150A1Method of treating multiple myeloma using combination therapies based on anti-cs1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4758US2017348429A1ANTI-cMET ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USEABBVIE BIOTHERAPEUTICS INC·Filed 2017·Application pending·0 cites
- 4857US2014322201A1Methods of treating multiple myeloma using combination therapies based on anti-cs1 antibodiesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Application pending·0 cites
- 4957US2018148513A1Anti-pd-1 antibodies and their usesABBVIE BIOTHERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 5056US2015051081A1Method of screening complex protein libraries to identify altered propertiesABBVIE BIOTHERAPEUTICS INC·Filed 2013·Application pending·0 cites
Showing the top 50 of 66 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →